Coronavirus disease (COVID-19) is an infectious disease caused by the coronavirus SARS-CoV-2. Here we have collected APR news related to the COVID-19 pandemic, vaccination efforts and emerging treatments.
Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received expanded emergency use authorization (EUA) from the FDA to provide a two-dose primary series for active ...
read more
Ascletis Pharma announced that the China National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application of ASC10, an oral inhibitor drug candidate targeting ...
read more
Merck and Orna Therapeutics are collaborating to discover, develop, and commercialize multiple drug modalities, including vaccines and therapeutics in the areas of infectious disease and oncology.
read more
Novavax announced that it submitted an application to the FDA for Emergency Use Authorization (EUA) of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus ...
read more
Novavax announced the initiation of its Phase 2b/3 Hummingbird™ clinical trial. The trial will evaluate the safety, effectiveness (immunogenicity), and efficacy of two doses of the Novavax
read more
SARS-CoV-2, the virus responsible for the global COVID-19 pandemic, has caused millions of infections and more than five million deaths worldwide to date. Although the speed with which COVID-19 ...
read more
The events of the past two years have made a profound impact on biopharmaceutical companies and every cog in the wheel of our industry. Internally, firms were forced to make radical shifts in ...
read more
Pfizer and BioNTech initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine ...
read more
The Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for primary immunization to prevent...
read more
Valneva announced that the European Commission (EC) approved an amendment to the Advance Purchase Agreement (APA) signed in November 2021 for Valneva’s inactivated whole-virus COVID-19 vaccine, ...
read more
Novavax, Inc. announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the FDA to provide a two-dose primary series for active ...
read more
Novavax, Inc. announced an agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense, to secure an initial 3.2 million doses of Novavax' ...
read more
COVID-19 vaccine acceptance increased 3.7% between 2020 and 2021, according to a new study from researchers at the CUNY Graduate School of Public Health and Health Policy (CUNY SPH), the Barcelona ...
read more
CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences announced the latest funding award under CEPI’s US $200m program to advance the development of vaccines that provide ...
read more
Ascletis Pharma Inc. annunced that the Investigational New Drug (IND) application of ASC10, an oral inhibitor drug candidate targeting RNA-dependent RNA polymerase (RdRp) for Coronavirus Disease 2019 ...
read more